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Variants in the gene encoding the enzyme glutamic acid decarboxylase like 1 (GADL1) have been
associated with response to lithium therapy. Both GADL1 and the related enzyme cysteine sulﬁnic acid
decarboxylase (CSAD) have been proposed to be involved in the pyridoxal-50-phosphate (PLP)-dependent
biosynthesis of taurine. In the present study, we compared the catalytic properties, inhibitor sensitivity
and expression proﬁles of GADL1 and CSAD in brain tissue. In mouse and human brain we observed
distinct patterns of expression of the PLP-dependent decarboxylases CSAD, GADL1 and glutamic acid
decarboxylase 67 (GAD67). CSAD levels were highest during prenatal and early postnatal development;
GADL1 peaked early in prenatal development, while GAD67 increased rapidly after birth. Both CSAD and
GADL1 are being expressed in neurons, whereas only CSAD mRNA was detected in astrocytes. Cysteine
sulﬁnic acid was the preferred substrate for both mouse CSAD and GADL1, although both enzymes also
decarboxylated cysteic acid and aspartate. In silico screening and molecular docking using the crystal
structure of CSAD and in vitro assays led to the discovery of eight new enzyme inhibitors with partial
selectivity for either CSAD or GADL1. Lithium had minimal effect on their enzyme activities. In conclu-
sion, taurine biosynthesis in vertebrates involves two structurally related PLP-dependent decarboxylases
(CSAD and GADL1) that have partially overlapping catalytic properties but different tissue distribution,
indicating divergent physiological roles. Development of selective enzyme inhibitors targeting these
enzymes is important to further dissect their (patho)physiological roles.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Lithium salts are among the most effective pharmacological
agents used in psychiatry. Although several molecular targets have
been identiﬁed, including protein kinases and enzymes involved in
phosphoinositide metabolism, lithium's mode of action at thearboxylase; ADC, Aspartate
ndrome type 1; BSA, Bovine
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Ltd. This is an open access articlecellular and molecular level is still being debated (Malhi et al.,
2013). A strong genetic association between variants in the hu-
man glutamic acid decarboxylase like 1 (GADL1) gene and the
response to lithium therapy in bipolar patients was recently re-
ported (Chen et al., 2014). Although these ﬁndings were not repli-
cated in other clinical samples (Cristiana et al., 2015), these results
are intriguing and warrants a biochemical investigation on GADL1
and the effects of lithium on this enzyme.
Human GADL1 was recently found to function as a cysteine
sulﬁnic acid decarboxylase and postulated to be involved in taurine
and possibly also b-alanine and carnosine production in vivo (Liu
et al., 2012). The sulfur amino acid taurine (2-amino-ethane-
sulfonic acid) is abundant in mammalian tissues and has been
implicated in many physiological functions. Taurine has a regula-
tory role in maintenance of osmotic pressure and preservation of
structural integrity of biological membranes (Hoffmann andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Phylogenetic tree of PLP-dependent decarboxylases. Amino acid sequences of
PLP-dependent decarboxylases were aligned using ClustalW version 2 software (2007)
(Larkin et al., 2007). The phylogenetic tree was constructed by the neighbor-joining
method based on alignment using the data base accession numbers: Q80WP8 (GADL1),
Q9DBE0 (CSAD), P48318 (GAD1), P48320 (GAD2), O88533 (AADC), P23738 (HDC),
A7U8C7 (ADC). The percentages of the amino acid sequence similarity to GADL1 are
given in parenthesis. All the sequences are fromMus musculus, except for ADC, which is
from Tribolium castaneum.
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taurine maymodulate protein phosphorylation (Lombardini, 1994),
serve as a trophic factor (Hernandez-Benitez et al., 2010; Pasantes-
Morales and Hernandez-Benitez, 2010), or act as a neurotrans-
mitter/neuromodulator (Jia et al., 2008). In several species, taurine
deﬁciency has been linked to speciﬁc disease states (Schaffer et al.,
2010) and also in humans dietary intake of taurine in the form of
energy drinks or vitamin supplements is widespread, although
with unclear health implications (Bigard, 2010).
In mammalian tissues taurine is mainly synthesized from
cysteine in a three step sequential pathway, involving oxidation by
cysteine dioxidase (CDO, E.C. 1.13.11.20), decarboxylation by
cysteine sulﬁnic acid decarboxylase (CSAD, E.C. 4.1.1.29) and ﬁnally
oxidation of hypotaurine to taurine. Alternatively, taurine may be
formed from cysteamine by cysteamine dioxygenase (E.C.
1.13.11.19). The tissue distribution of the various enzymes involved
in cysteine metabolism seems to reﬂect different metabolic de-
mands of these tissues (Stipanuk et al., 2006). Thus, the protein
levels of liver CDO, which is rate limiting in the degradation of the
potentially toxic amino acid cysteine are tightly regulated in
response to cysteine load (Stipanuk et al., 2009).
In comparison, the physiological role and regulation of CSAD
and GADL1 are less understood. Mammalian CSAD has been iso-
lated from liver, kidney and brain where it exists as a dimer with a
reported subunit molecular mass of approx. 43e55 kDa (Heinamaki
et al., 1982; Tang et al., 1996; Tappaz et al., 1998). GADL1 is
expressed in muscle and kidney tissue (Liu et al., 2012). However,
its pattern of expression in other tissues, including brain is not
known. CSAD and GADL1 belong to a large family of pyridoxal-50-
phosphate (PLP)-dependent enzymes that catalyze a range of
different reactions, such as decarboxylation, transamination, race-
mization or eliminations using amino acids or related substrates
(Toney, 2011). Crystal structures of many PLP-dependent enzymes,
including CSAD, have been published (http://www.rcsb.org/pdb/
explore/explore.do?structureId¼2JIS).
In the brain, CSAD has mainly been detected in astrocytes in
cerebellum and hippocampus (Reymond et al., 1996a), although
there are also reports of CSAD being found in neurons (Chan-Palay
et al., 1982). Based on the different tissue distribution of CDO and
CSAD, it was proposed that the taurine synthesis pathway is initi-
ated in neurons and completed in astrocytes (Dominy et al., 2004).
More recently, taurine biosynthesis from cysteine in murine neu-
rons and astrocytes was reported, indicating that the complete
enzymatic machinery for taurine synthesis is present in both cell
types (Vitvitsky et al., 2011). However, the identity of the enzymes
involved in the synthesis in the two cells types is not known.
A CSAD knockout mouse was recently described (Park et al.,
2014). The plasma levels of taurine were reduced by 83% in
CSAD/ mice and most offspring from 2nd generation CSAD/
mice died shortly after birth, indicating an important physiological
role of CSAD.
The aims of our studywere (i) to determine the effects of lithium
on GADL1 and CSAD, (ii) to compare the substrate speciﬁcities of
these enzymes, to use this knowledge to ﬁnd inhibitors of the en-
zymes and (iii) to study their cellular, regional and temporal pat-
terns of expression in the mammalian brain.
2. Experimental procedure
2.1. Source of materials
Chromatography materials for enzyme puriﬁcation were pur-
chased from GE Healthcare Life Sciences (Uppsala, Sweden), unless
otherwise indicated, and all other reagents were from Sigma (St
Louis, MO, USA).2.2. Molecular modeling/docking of substrates in GADL1 and CSAD
To determine the structural relationships of GADL1, CSAD, and
other decarboxylases, we created a homology model of GADL1. The
sequence of GADL1 was aligned with that of CSAD in DeepView
(Guex and Peitsch, 1997) and submitted to the Swiss-Model server
(Schwede et al., 2003) to prepare a homology model of GADL1 (see
Fig. 2). A virtual library of 8 million commercially available com-
pounds was obtained from the ZINC database (Irwin et al., 2012)
and docked into the active site of CSAD with the Glide software
(Friesner et al., 2004) from Schrodinger®. A grid centered on the PLP
cofactor in the CSAD binding site was deﬁned with dimensions 17 Å
in all three dimensions. The compounds were initially docked
following the high throughput virtual screening protocol. The top
100,000 compounds were redocked following the standard preci-
sion protocol. Finally, the 10,000 top scoring compounds from this
procedure were docked into the active site with the extra precision
(Friesner et al., 2006) protocol.2.3. Expression vectors
Multiple mRNA transcripts of CSAD and GADL1 have been
described, probably due to alternative initiation codons and
splicing events (Tappaz et al., 1999). The UniProt database (http://
www.uniprot.org/uniprot/) lists three human CSAD sequences
with 346e520 amino acids, two human GADL1 isoforms with
418e521 amino acids and two mouse GADL1 isoforms with
526e550 amino acids. We obtained cDNA clones corresponding to
the 550 amino acids (62 kDa; Q80WP8-2) isoform of mouse GADL1
Fig. 2. A Homology model of dimeric GADL1 based on CSAD (pdb code 2JIS). One of the subunits (colored green) is represented with transparent surface to get an impression of the
overall structure. The PLP cofactor is represented by spheres with size corresponding to the Van der Waal radius, colored by atom type and covalently linked to Lys333 (not shown)
in the active site. B Representation of the putative substrate binding site in GADL1 with highlighted amino acids in close proximity to the substrate. PLP is shown with a covalent
bond to Lys333. The model of GADL1 with GABA in the putative substrate binding site was prepared by aligning the GADL1 homology model with the coordinates of GAD67 in
complex with GABA (pdb code 2OKJ). C Representation of the substrate binding site in CSAD with highlighted amino acids in close proximity to the substrate; Arg466, Gln92 and
Leu93. PLP is shown with a covalent bond to Lys305. The model of CSAD with GABA in the putative substrate binding site was prepared by aligning the CSAD coordinate ﬁle (2JIS)
with the coordinates of GAD67 in complex with GABA (pdb code 2OKJ).
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Three different expression vectors were used using maltose-
binding protein (MBP) as a fusion partner; pETM41: for 6His-
MBP-CSAD and 6His-MBP-GADL1 expression in Escherichia coli
and pCMV-SPORT 6: for expression of native CSAD and pCRII-Topo
for native GADL1 in an in vitro transcription/translation system
(ITT), essentially as described previously (McKinney et al., 2005).
The sequences of all CSAD and GADL1 expression clones were
veriﬁed by DNA sequencing.
2.4. Cell free transcription and translation of CSAD and GADL1
A rabbit reticulocyte lysate (Promega, Madison, WI) was used to
express CSAD and GADL1 where 1 mg of plasmid DNA per reaction
(50 mL) and 1 h incubation (30 C) was used. Enzyme activity wasassayed immediately following removal of unincorporated amino
acids by gel ﬁltration using 0.5 mL pre-packed Zeba™ spin columns
(Pierce, Rockford, IL, USA), which were prerinsed with buffer:
20 mM NaHepes 200 mM NaCl and 10% glycerol. Speciﬁc expres-
sion levels were determined after gel ﬁltration and separation on
12% SDS-PAGE by integration of [35S] methionine labeled CSAD and
GADL1 band intensities using the Personal Molecular Imager™
System and Quantity One Software v. 4.5.2 (Bio-Rad, Hercules, CA,
USA).
2.5. Analysis of CSAD and GADL1 expressed in E. coli
Heterologous expression of CSAD and GADL1 fusion proteins in
E. coli was essentially performed as described (Winge et al., 2007)
except for the following changes: BL21-CodonPlus (DE3)-RIPL
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duction temperature was reduced to 20 C. Cell pellets were lysed
by sonication in 20 mM Hepes pH 7.4, 200 mM NaCl, 10% glycerol,
10 mM benzamidine, 1 mg/mL lysozyme, 1 mg/mL pepstatin A,
4.6 mg/mL leupeptin. PMSF was added immediately following
sonication to a concentration of 1 mM. The cell lysate was frac-
tioned into soluble and insoluble parts by centrifugation at
10.000  g for 30 min. An equal volume of lysate buffer was added
to the pelleted fraction and homogenized. Speciﬁc expression levels
of fusion proteins were determined by analyzing equal amounts
(30 mg) of the soluble fractions by separation on 12% SDS-PAGE.
Coomassie stained 6  HisMBP-CSAD and GADL1 fusion protein
band intensities were integrated using the VersaDoc MP 4000
imaging system and Quantity One Software (Bio-Rad, Hercules, CA,
USA).2.6. Activity assays
Activities of CSAD, GADL1 and GAD65 were measured using
both ITT-expressed protein and E. coli expressed protein. A reaction
mixture of 100 ml containing varying amounts of puriﬁed recom-
binant proteins and amino-acids was prepared in 60mMpotassium
phosphate (pH 7.4) containing 5mMDTT, 50mM sucrose and 0.5 or
100 mM PLP. Adding 1 mM of the amino acid substrate started the
reaction. Samples of 30 ml were taken at 15e60 min and the reac-
tion stopped by addition of an equal volume of ice-cold ethanol
with 5% acetic acid. The samples were then centrifuged at
15.700 g for 10 min before the supernatant was being transferred
to a microtiter plate and analyzed by HPLC. Samples were diluted to
50% in solvent (24% ethanol in 50 mM Na-phosphate pH 6.0), and
4.2% o-phtaldialdehyde (OPA)-reagent was added before injection
into a Zorbax Eclipse XDB-C18 column. Determination of product in
the reaction-mixture was based on ﬂuorescence detection of OPA-
bound amino acid at 366/455 nm.
In order to perform inhibition assays on the two enzymes,
different concentrations of the inhibitors were tested
(0.001e50 mM). The assay was performed as described above at
37 C for 60 min and stopped by addition of equal volume of ice-
cold ethanol with 5% acetic acid.2.7. Gene expression assays
Total RNA was obtained from Clontech laboratories, Mountain
View, California, USA (brain, liver, muscle and kidney) and Scien-
cell, Carlsbad, USA (neurons and astrocytes). Total cDNA was ob-
tained using High Capacity RNA-to-cDNA kit from Applied
Biosystems (Foster city, CA). Gene-speciﬁc primers (Suppl. Table 1),
TaqMan®Minor Groove Binder (MGB) probes and Assay-on-De-
mand™ PCR reagents were from Applied Biosystems and were
designed to be gene-speciﬁc and target all reported splice variants
of GADL1 and CSAD (Suppl. Table 2). Each real-time PCR reaction
was run in triplicate and contained 1 ml TaqMan® primer/probe.
Cycling parameters were 95 C for 10 min, followed by 40 cycles of
95 C for 15 s and 60 C for 1 min. Serial diluted standards were
used to prepare a standard curve, which was run on the same plate
and used to calculate relative gene expression abundance. The
results were quantiﬁed by the DDCt method using the house-
keeping genes GAPDH and b-actin as endogenous controls to
adjust for unequal amounts of RNA and efﬁciency of cDNA syn-
thesis. None of the samples showed signs of DNA contamination
when reverse transcriptase was omitted from the cDNA reaction.
The relative gene expression levels are presented as 2DDCt using
CSAD as the control.2.8. Western blot analysis
Frozenmouse tissues (200 mg) were lysed in ice-cold lysis buffer
containing protease inhibitors. The lysates were centrifuged at
16.000  g for 10 min at 4 C. The supernatants were collected and
stored at 80 C. Protein concentrations were determined and
20 mg of total protein or 10 ng of puriﬁed CSAD or GADL1 protein
were analyzed on 10% TGX Stain-Free gels (Bio-Rad) for 45 min at
20 mA/gel. The gel was activated and imaged (see “Imaging and
data analysis” section below). The activated gel was transferred to
an Immun-Blot nitrocellulose membrane (Bio-Rad) in 7 min using
the Trans-Blot Turbo Transfer System (Bio-Rad) with Trans-Blot
Turbo Midi Transfer Packs. Pre-made western blots of protein
samples from mouse brain sampled at 11 different developmental
stages (MW-201-D) and adult brain tissues from 14 different spe-
cies (AW-201) were also obtained from Zyagen Laboratories, San
Diego, CA. The membranes were blocked with 5% bovine serum
albumin (BSA),1% glycine and 0.1% Tween-20 in Tris-buffered saline
and incubated with custommade afﬁnity puriﬁed sheep antibodies
generated against puriﬁed human CSAD or human GADL1 MBP
fusion proteins (James Hastie, University of Dundee). To avoid cross
reactivity against these related proteins, the GADL1 antibodies
were ﬁltered against puriﬁed CSAD and the CSAD antibodies were
ﬁltered against puriﬁed GADL1. Antigens were detected using
horseradish peroxidase-conjugated goat anti-sheep antibody
(1:10.000) (Bio-Rad Laboratories, Hercules, CA) as a secondary
antibody and enhanced chemiluminescence detection.
We also tested commercial rabbit antibodies against either hu-
man CSAD (SigmaeAldrich HPA039487; 1:2.000, immunogen
peptide corresponding to amino acids 52e110 in the CSAD protein
sequence), anti-GADL1 (SigmaeAldrich SAB2103888; 1:1000,
immunogen 159e208) or anti-GADL1 (Thermo Scientiﬁc, Rockford,
IL, PA5-13434; 1:100, immunogen 224e254). The Sigma anti-
Glutamic Acid Decarboxylase 65/67 (Anti-GAD65/67) antibody
from rabbit (G5163, Immunogen human GAD67 amino acids
579e594) was also used (1:10.000). The commercial CSAD anti-
bodies all reacted against the respective MBP fusion proteins, as
well as with the cleaved puriﬁed enzymes. Although the antibodies
were raised against three different immunogens and marketed to
be speciﬁc against either of these enzymes, they all showed some
cross reactivity with the other enzyme (Suppl. Fig. 1). This lack of
speciﬁcity is also reﬂected in the recently published Human protein
atlas (http://www.proteinatlas.org/), where two commercially
available antibodies against each of GADL1 and CSAD show multi-
ple protein bands and little internal consistency.
This is in contrast to our custom made sheep CSAD and GADL1
antibodies that were speciﬁc for their respective proteins and were
judged to be more reliable in studies of tissues with low levels of
expression of these proteins. None of the antibodies showed cross
reactivity against hGAD1, whereas the commercial antibody raised
against GAD67 showed some cross reactivity against both CSAD and
GADL1 (Suppl. Fig. 1).
2.9. Imaging and data analysis
Housekeeping genes as GAPDH are being expressed at different
levels in the different tissues (Eaton et al., 2013). It is therefore
difﬁcult to ﬁnd an antibody to use as a loading control when
comparing different tissues. Using TGX Stain-Free gels (Bio-Rad) we
were able to normalize the western blots with total protein as
described in Gurtler et al. (Gurtler et al., 2013). CSAD and GADL1
signals were automatically normalized using ImageLab software
with either the intensity values of GAPDH or Stain-Free total lane
volumes. The normalized datasets were used for the calculation of
CSAD/GADL1 levels. In addition, t-tests (double-sided and paired)
Fig. 3. Substrate dependence and inhibition of CSAD and GADL1. Substrate depen-
dence of puriﬁed GADL1 (triangles) and CSAD (circles) using CSA (open symbols) or
Asp (ﬁlled symbols) as substrates (n ¼ 10). The assay was performed as described
above at 37 C for 60 min and stopped by addition of equal volume of ice-cold ethanol
with 5% acetic acid.
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uate the statistical signiﬁcance of the calculations.
3. Results
Genome databases contain many sequences within the family of
the PLP-dependent enzymes, including GAD65 and GAD67, aro-
matic amino acid decarboxylase (AADC), histidine decarboxylase
(HDC), aspartate decarboxylase (ADC), CSAD and GADL1. Although
the terminology “GADL1” probably is based upon its sequence
similarity to GAD (45e47% amino acid identity), a sequence com-
parison shows that it is more similar to ADC (49%) and to CSAD
(61%) (Fig. 1). The three-dimensional structure of GADL1 is not
known. However, the structures of human CSAD (pdb accession
code 2JIS), GAD67 and GAD65 (pdb codes 2OKJ and 2OKK, respec-
tively) are deposited in the protein data bank. This information can
be used to model the structure of GADL1.
3.1. Homology modeling
A homology model of GADL1 was prepared with CSAD as tem-
plate in SwissModel http://www.rcsb.org/pdb/explore/explore.do?
structureId¼2JIS (Fig. 2A). The structure of CSAD was solved in
complex with the PLP, without substrate present. However, the
structures of GAD67 and GAD65 are of the ternary complexes with
both cofactor and product (gamma-amino-butanoic acid, GABA)
present in the proposed substrate-binding site. Superimposition of
our GADL1 homology model and CSAD with GAD65 and GAD67
thus provided a structural model of GADL1 and CSAD in ternary
complex with cofactor and GABA in the postulated substrate-
binding site (Fig. 2B and C).
Inspection of this model revealed some amino acid residues that
may be critical for enzyme function. A Schiff base linkage (internal
aldimine) between PLP and Lys405 of the active site in GAD65 has
been described (Fenalti et al., 2007). In our homology model of
GADL1 PLP is covalently attached to Lys333. Furthermore, His219 of
GADL1 is involved in base stacking with PLP. This residue corre-
sponds to the conserved base-stacking residue His191 in CSAD and
His 291 in GAD67 (Qu et al., 1998). This residue is found in two
possible conformations in CSAD and the equivalent His in GAD65/
67 is postulated to be involved in regulation of enzymatic activity
through interactions with the activation loop.
The activation loop of human GAD65 comprises a stretch of 11
residues from Ala432 to Tyr442 (Ala-Gly-Tyr-Leu-Phe-Gln-Pro-
Asp-Lys-Gln-Tyr) with Tyr434 being involved in catalysis. This
stretch of amino acids corresponds to 361e371 in GADL1 (Ala-Ser-
Tyr-Leu-Phe-Gln-Gln-Asp-Lys-Phe-Tyr) including the conserved
catalytic tyrosine residue, Tyr363 in GADL1 (corresponding to
Tyr335 in human CSAD and Tyr322 in human AADC).
The carboxyl group of the product (GABA) in GAD67 is found to
form a salt bridge with Arg567 and a hydrogen bond with Gln190
(Fenalti et al., 2007). These two residues correspond to Arg494 and
Gln120 in our homology model and are thus likely to be involved in
interactions with the GADL1 substrate. Furthermore, the structure
of GAD from E. coli in complex with the substrate analogue gluta-
rate points to Thr62 (corresponding to Gln120 in GADL1) as
important for substrate binding.
3.2. GADL1 and CSAD form dimers in solution
Using cDNA of the coding reading frame frommouse, the GADL1
and CSAD sequences were cloned into vectors for both mammalian
and bacterial expression. The proteins expressed in bacteria were
fused to MBP to increase their solubility and facilitate puriﬁcation.
They were expressed and puriﬁed as described in ExperimentalProcedures. When purifying the proteins on a gel-ﬁltration column
after cleavage with TEV, CSAD and GADL1 had apparent molecular
masses of 115 kDa and 137 kDa, respectively, suggesting that they
are both present as dimers. Although both proteins have a tendency
to aggregate in solution, it appears that GADL1 has the highest
solubility (results not shown). When analyzed on SDS-PAGE, CSAD
and GADL1 appear at almost the same molecular weight, i.e. as
99 kDa as fusion proteins (MBP-CSAD or MBP-GADL1) or as cleaved
proteins at 56 kDa (CSAD) and 59 kDa (GADL1), respectively (MBP
has a molecular weight of 45 kDa) (Suppl. Fig. 1).3.3. GADL1 and CSAD have overlapping substrate speciﬁcities
When we performed activity assays with the standard protei-
nogenic amino acids and some abundant occurring dicarboxylic
acids as substrates for CSAD, GAD and GADL1, few compounds
displayed signiﬁcant activity with either enzyme (Suppl. Table 3).
However, cysteic acid (CA), homocysteic acid, CSA and Asp were
decarboxylated by both GADL1 and CSAD at different rates (Fig. 3,
Table 1 and data not shown). Notably, no production of GABA from
glutamate was observed for either CSAD or GADL1, whereas, as
expected, GAD catalyzed this reaction (data not shown). These data
suggest that mouse CSAD and GADL1 aremore similar to each other
than they are to GAD, as the sequence comparison also suggests
(Fig. 1).3.4. Kinetic properties of CSAD and GADL1
Using different concentrations of CSA and Asp, we determined
the kinetic properties of CSAD and GADL1 (Table 1). Whether
analyzed as fusion proteins with MBP or as pure, cleaved enzymes,
the activity towards CSA was higher for CSAD than for GADL1
(p ¼ 0.0001), whereas GADL1 had much higher Vmax values than
CSAD for decarboxylation of Asp (p ¼ 0.003). For both substrates,
the fusion proteins and the puriﬁed cleaved enzymes had similar
Km values, but the Vmax values were highest for the pure decar-
boxylases. Using CSA as substrate, the speciﬁcity constants (Kcat/Km)
were much higher for CSAD than for GADL1, whereas the opposite
was true using Asp as substrate. The Km value for decarboxylation of
Table 1
Kinetic parameters of recombinant CSAD and GADL1 using CSA and aspartate as substrates. Activity assays were performed as described in the method-section. The results are
presented as means ± S.E.M. of three separate measurements using different enzyme preparations. The kinetic values were calculated based on predicted subunit masses of
55 kDa (493 aa) for mouse CSAD, 57 kDa (502 aa) for mouse GADL1,100 kDa formouseMBP CSAD and 102 kDa forMBP GADL1. Human CSAD has a predictedmass of 55,023 kDa
(493 aa) and human GADL1 is predicted to be 59 246 kDa (521 aa). *Substrate inhibition, KSi CSA: 26 ± 10 mM for cleaved CSAD.
CSA (0e50 mM) Aspartate (0e50 mM)
Enzyme form Vmax (mmol/min/mg) Km (mM) kcat (s1) kcat/Km (mM1 s1) Vmax (mmol/min/mg) Km (mM) kcat (s1) kcat/Km (mM1 s1)
Fusion
proteins
CSAD 0.33 ± 0.046* 0.14 ± 0.11 0.55 3.9 0.025 ± 0.003 23.0 ± 6.7 0.04 0.0017
GADL1 0.74 ± 0.055 1.74 ± 0.56 1.3 0.75 0.66 ± 0.02 21.3 ± 1.5 1.2 0.056
Cleaved
proteins
CSAD 7.22 ± 1.26* 0.20 ± 0.06 6.6 33 0.16 ± 0.027 93 ± 32 0.14 0.0015
GADL1 3.84 ± 0.034 1.12 ± 0.06 3.6 0.94 1.41 ± 0.10 31.7 ± 4.7 1.3 0.041
Fig. 4. A. Effect on CSAD (circles) and GADL1 (triangles) by MnCl2 (closed symbols) and
LiCl (open symbols). * Signiﬁcantly different from control (t-test, p < 0.05). Data are
expressed as average ± STDEV (n ¼ 3) B Inhibition of CSAD (circles) and GADL1 (tri-
angle). The different compounds used are Bis-(carboxymethyl)-trithiocarbonate (Red,
compound A), Ethylxanthogenacetic acid (Green, compound B) and 2,5-disulfoaniline
(Blue, compound G). Different concentrations of the compounds were tested
(0.05e40 mM for the salts and 0.001e50 mM for the inhibitors) using a standard
concentration of CSA (100 mM). The assay was performed as described above at 37 C
for 60 min and stopped by addition of equal volume of ice-cold ethanol with 5% acetic
acid. Data are expressed as average ± STDEV (n ¼ 3).
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that reported for puriﬁed rat liver CSAD (0.17 mM) (Guion-Rain and
Chatagner, 1972). Although the Km value for decarboxylation of CSA
by mouse GADL1 (1.12e1.74 mM) was similar to recently reported
values for human GADL1 (1.14 mM) (Liu et al., 2012), the mouse
enzymes had 2e3 fold higher speciﬁc activities (Table 1). Inter-
estingly, the Km values were much higher and the speciﬁcity con-
stants for decarboxylation of Asp were much lower for mouse
GADL1 and CSAD than reported for the recombinant human GADL1
(Liu et al., 2012). A comparison of these constants revealed that
compared to GADL1, CSAD had a 1000-fold higher selectivity to-
wards CSA. A pronounced substrate inhibition by CSAwas apparent
for CSAD (KSi ¼ 26 ± 10 mM), but this was not observed for GADL1
in this substrate concentration range (Fig. 3). Both GADL1 and CSAD
catalyzed decarboxylation of CA to taurine, at rates of 12e13% of
that observed for the conversion of CSA to hypotaurine (data not
shown). Using equimolar concentrations of CA and CSA (1 mM), CA
decarboxylation by the competing substrate was inhibited by
49e56% for both enzymes, while the CSA decarboxylation was
inhibited by only 5e15% for GADL1 and CSAD, respectively; illus-
trating that CSA is the preferred substrate for both enzymes.
3.5. Effects of metal ions
As reported for pig brain CSAD (Tang et al., 1996), mouse CSAD
was activated by addition of manganese ions (52% stimulation in
the presence of 0.4 mM MnCl2, p ¼ 0.003), but this effect was not
present for GADL1 using similar assay conditions. The enzyme ac-
tivities of CSAD and GADL1 were essentially unaffected by Liþ using
ﬁnal concentrations of LiCl from 0.05 to 40 mM, however, for
GADL1 a weak stimulation was observed in the presence of
0.2e0.4 mM Liþ (p ¼ 0.03) (Fig. 4A).
3.6. Inhibitors of CSAD and GADL1
To further characterize the substrate and inhibitor speciﬁcities
of GADL1 and CSAD, we performed in silico docking into the active
site of CSAD of a subset of the ZINC database of different com-
pounds [28] and tested the top 20 compounds in vitro. As shown in
Table 2 and Fig. 4B, bis-carboxymethyl-trithiocarbonate (Com-
pound A) was the compoundwith highest afﬁnity for both enzymes
(Ki z 70 and 60 mM for CSAD and GADL1, respectively). Removing
the two terminal carboxyl oxygens and substituting the adjacent
thioether into an ether increased the selectivity for GADL1 over
CSAD (compound B). Removing the central thioketone of Com-
pound A gave rise to Compound C with selectivity for CSAD over
GADL1, although at a signiﬁcantly lower afﬁnity for both. Com-
pound E was the most selective CSAD inhibitor of the compounds
tested. Although none of the compounds were potent inhibitors of
either enzyme, their relative selectivity might be exploited to
produce even more speciﬁc compounds.
Glutamate was completely inactive as inhibitor of either CSADor GADL1, indicating that none of these enzymes are involved in
glutamate metabolism. In contrast to the recently reported insen-
sitivity of CSAD towards inhibition by L-cysteine [40], the latter
compound completely inhibited the CSAD activity (>95%) of both
Table 2
Speciﬁcity of CSAD and GADL1 inhibitors. Different concentrations of the inhibitors were tested (0.1e50 mM). The assay was performed as described above at 37 C for 60 min and stopped by addition of equal volume of ice-cold
ethanol with 5% acetic acid.
Compound Name Zinca CSAD IC50 ± S.E. (mM) GADL1 IC50 ± S.E. (mM) CSAD Ki ± S.E. (mM) GADL1 Ki ± S.E. (mM) Selectivity 2D structure
A Bis-(carboxymethyl)-
trithiocarbonate
01661333 0.12 ± 0.029 0.068 ± 0.013 0.07 ± 0.04 0.06 ± 0.03 1.09
B Ethylxanthogenacetic acid 01760604 0.43 ± 0.23 0.098 ± 0.012 0.25 ± 0.28 0.09 ± 0.02 2.71
C MethyleneBis thioglycolic acid 01635711 1.6 ± 0.53 2.7 ± 0.21 0.93 ± 0.66 2.55 ± 0.44 0.36
D Imidazolidinyl urea 04245708 2.72 ± 0.92 1.30 ± 0.52 1.59 ± 1.14 1.23 ± 1.00 1.29
E 4 sulfophtalic acid 01693949 0.97 ± 0.3 7.4 ± 0.94 0.57 ± 0.37 7 ± 1.89 0.08
F Bi(cyclopropane)-2,2,3,3
tetracarboxylic acid
25722391 7.3 ± 1.3 10.0 ± 0.35 4.26 ± 1.68 9.46 ± 0.81 0.45
G 2,5-disulfoaniline 01687023 5.3 ± 1.0 2.4 ± 0.6 3.09 ± 1.29 2.27 ± 1.17 1.36
H L-cysteine 00895042 1.44 ± 0.45 0.92 ± 0.10 0.84 ± 0.56 0.87 ± 0.20 0.97
a Accession number in Zinc database (Irwin et al. 2012)
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showed that the inhibitors were competitive against CSA (data not
shown). Furthermore, as the most potent inhibitors were substrate
analogs and the inhibition constants were unaffected by 10-fold
dilution of target enzyme or the addition of 0.1 mg BSA in the
assay, they probably inhibit GADL1 and CSAD by binding to the
enzymes’ active sites. It is unlikely that the enzyme inhibition is due
to the formation of colloidal aggregates by the inhibitors (Feng
et al., 2007), or other non-speciﬁc effects.3.7. CSAD and GADL1 expression patterns
The tissue distribution of CSAD has been controversial (Tang
et al., 1996; Tappaz et al., 1999; Vitvitsky et al., 2011). Since many
studies were done before the discovery of GADL1, it was important
to establish whether the reported discrepancies could be due to
contamination of CSAD preparations with GADL1. For this purpose,
we systematically compared the mRNA and protein levels for CSAD
and GADL1 in mouse tissues. The mRNA levels were determined by
real-time reverse transcriptase (RT) -PCR quantiﬁcation using
speciﬁc DNA probes (Suppl. Table 1). As shown in Fig. 5A, the level
of CSAD mRNAwas much higher in mouse liver and kidney than in
total brain extracts (4 (p ¼ 1  106) and 7 times (p ¼ 4  1010)Fig. 5. Gene expression of CSAD and GADL1 in different tissues. A Adult mouse tissues.
B Adult human tissues. Total poly-A þ RNA was reverse transcribed and the cDNA
ampliﬁed by real-time PCR using speciﬁc primers for CSAD or GADL1. The PCR products
were detected with TaqMan® detection assay. PCR values were normalized to those
produced with primers for GAPDH and b-actin and presented as average ± STDEV
(n ¼ 3). All values were signiﬁcantly different between tissues and proteins (p < 0.05).higher, respectively), and almost no CSAD mRNA was detected in
the muscle, as reported previously (Ide et al., 2002; Park et al.,
2002; Reymond et al., 2000). For GADL1 only low levels of mRNA
were observed in adult brain compared with CSAD (p ¼ 0.001), but
was not detected in liver and kidney samples. However, in contrast
to CSAD, mRNA of GADL1 was detected in skeletal muscle
(p¼ 0.005), as was also reported by Liu et al. (Liu et al., 2012). These
results were also conﬁrmed by western blot experiments (Fig. 6),
although the amount of CSAD detected in kidney was lower than in
brain and liver (p ¼ 0.01 and 0.0005).
Although taurine is found in both astrocytes and neurons, CSAD
is more abundant in non-neuronal cells (Tappaz et al., 1998). It has
been proposed that astrocytes produce taurine via CSAD, whileFig. 6. Protein expression of CSAD and GADL1 in different tissues. Representative
western blot image of CSAD, GADL1 and GAPDH in mouse brain, olfactory bulb, liver,
muscle and kidney (20 mg, 3 weeks old, n ¼ 3). Recombinant mCSAD, mGADL1 and
hGAD1 were used as controls. A representative image of the stain free gel is shown
under the immunoblots showing the total protein in the samples. The signals from 3
different samples are expressed as average ± STDEV in the bar chart. * Signiﬁcantly
different p < 0.05. Signals were normalized against both GAPDH and total protein
(using stain-free gels from Bio-Rad).
Fig. 7. Protein expression of CSAD and GADL1 in brain. A Representative western blot
image of CSAD, GADL1, GAD65/67 and Beta-actin/GAPDH in total brain lysates (70 mg)
from mice at different developmental stages and different ages (embryonic day 17 to
12 months old, Zyagen Laboratories). B Representative western blot image of CSAD and
Beta-actin/GAPDH in total brain lysates (70 mg) from 14 different species (Zyagen
Laboratories) using custom-made CSAD antibody 1. Human (55 years), 2. Mouse (10
weeks), 3. Rat (10 weeks), 4. Dog (2 years), 5. Rabbit (15 weeks), 6. Guinea Pig (15
weeks), 7. Hamster (10 weeks), 8. Chicken (1 year), 9. Bovine (3 years), 10. Sheep (3.5
years), 11. Porcine (3 years), 12. Equine (5 years), 13. Monkey Cymolgus (4 years), 14.
Mini Pig (2 years).
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pathway (Vitvitsky et al., 2011). To examine whether CSAD or
GADL1 could be involved in taurine biosynthesis in either neurons
or astrocytes, CSAD and GADL1mRNA levels weremeasured in both
cell types. As shown in Fig. 5B, CSAD was expressed at lower levels
in human astrocytes than in neuronal cells (p ¼ 0.0001), whereas
GADL1 was only expressed in neuronal cells. Although the level of
GADL1mRNAwas six-fold lower than those of CSAD (p¼ 1 107),
this enzyme might account for some of the CSAD-activity in neu-
rons (Vitvitsky et al., 2011). The Human Protein Atlas http://www.
proteinatlas.org/ also shows that both proteins are mainly present
in neurons. It also indicates the presence of GADL1 in astrocytes in
certain tissues such as hippocampus and cerebral cortex. However,
these results are uncertain as the antibody used in their study also
showed cross reactivity towards CSAD (results not shown).
Publicly available databases, such as the Allen Brain Atlas
(http://www.brain-map.org/), were also consulted to study the in
situ RNA hybridization patterns of GAD65/67, CSAD, and GADL1. A
comparison of their expression levels showed that although
GAD65/67 and CSAD in general are expressed at higher levels than
GADL1, certain brain regions, such as the olfactory bulb, have higher
levels of GADL1 than CSAD (Suppl. Fig. 2A). At protein levels, GADL1
appeared to be expressed at the same level as CSAD in the olfactory
bulb, but at very low levels in total brain lysates (p ¼ 0.003) (Fig. 6).
3.8. Developmental pattern of CSAD and GADL1 in mouse brain
In some tissues, CSAD expression has been reported to increase
with age (Tappaz et al., 1998), while in zebraﬁsh an important role
of CSAD in early embryogenesis was recently reported (Chang et al.,
2013). To investigate the pattern of GADL1 and CSAD expression
during development and compare it with GAD expression, we
immunoblotted total brain extracts from mice at 11 different ages,
from embryonic day 17 (E17) to 12 months. As shown in Fig. 7A,
striking differences were observed between the staining patterns of
the three antibodies. CSAD expression decreased with age, whereas
the expression of GAD increased and was strongest in adult brain,
consistent with its reported developmental pattern (Kim et al.,
2006; Ohkuma et al., 1986). However, when using speciﬁc anti-
bodies for GADL1, three weak bands were visible; a high molecular
weight species (65 kDa), that had similar developmental pattern as
CSAD, and two bands at 58e60 kDa that gradually disappeared
after E17. This protein intensity pattern corresponds well with
mRNA levels from the Human Brain transcriptome database (http://
hbatlas.org/), as shown in Suppl. Fig. 2B (Kang et al., 2011).
Although the detection of GADL1 in the total brain lysate was weak,
we cannot rule out the presence of the protein in speciﬁc parts of
the brain, such as was seen in the olfactory bulb.
3.9. Cross-species characterization of brain CSAD and GADL1
CSAD puriﬁed frommany sources and species has been reported
with subunit molecular masses of 43, 51, 53, or 55 kDa (Pasantes-
Morales et al., 1976; Skoldberg et al., 2004; Tang et al., 1996;
Weinstein and Grifﬁth, 1987; Wu, 1982). To examine cross-species
reactivity of the CSAD antibodies, and compare their protein
levels, total brain homogenates from 14 different species of adult
agewere analyzed bywestern blotting (Fig. 7B). Consistent with the
strong sequence similarities between mammalian CSAD enzymes,
comparable labeling intensity was obtained for most of these
species. Only one major CSAD band appeared at around 58 kDa
(Fig. 7B). In accordance with the low abundance and mainly em-
bryonic expression pattern of GADL1 expression, much weaker
bands appeared when the same samples were analyzed with anti-
GADL1 antibodies, making the comparison of this enzyme acrossspecies more subject to ambiguity (results not shown).
4. Discussion
Here we report a systematic comparison of murine CSAD and
GADL1 structures, biochemical properties and tissue expression
patterns.
4.1. Biochemical properties of CSAD and GADL1
In order to characterize these two proteins we ﬁrst developed a
new expression and puriﬁcation protocol. Although both enzymes
appeared to have a preference for decarboxylation of CSA, they
were also active against other substrates, with different substrate
speciﬁcities and sensitivity towards inhibitors. Glutamate was
completely inactive as substrate or inhibitor of either CSAD or
GADL1, indicating that none of these enzymes are involved in
glutamate metabolism. Thus, it is also unlikely that the observed
strong association between genetic variants GADL1 and response to
lithium treatment (p ¼ 2.52  1037) is related to altered produc-
tion of the inhibitory transmitter g-aminobutyric acid, as recently
suggested (Chen et al., 2014). The effects of metal ions on the
enzyme activities were tested using a wide range of concentrations
including the therapeutic range of Liþ used in human pharmaco
therapy. The minimal effect of lithium on either CSAD or GADL1
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genetic variants and the response to lithium therapy. As lithium is
eliminated via kidneys, it has been speculated that the association
between GADL1 variants and response to lithium therapy could be
mediated by renal GADL1 (Birnbaum et al., 2014). However, as the
response to lithium therapy was independent on renal clearance of
lithium (Chen et al., 2014) and the kidney levels of GADL1 are very
low, we consider this to be unlikely.
Alternative substrates and physiological functions of GADL1
should also be considered. The decarboxylation product of Asp (b-
alanine) produced by GADL1 or CSAD (Fig. 3) is a constituent of the
dipeptide carnosine. As for taurine, carnosine and its metabolic
derivatives may have antioxidant properties and are found in many
tissues, including muscle and brain (Boldyrev and Abe,1999). A role
of GADL1 in carnosine productionwas supported by recent genome
wide association studies showing a strong association between
human blood levels of N-acetyl carnosine and variants in the
GADL1 gene (p ¼ 3.4  1018 for rs7643891) (Shin et al., 2014).
Indeed, the tissue distribution of GADL1 seems to be compatible
with a physiological role of carnosine in muscle and possibly also
brain function. The role of b-alanine in brain function is less clear.
However, it is interesting that the plasma levels of this amino acid is
altered by selective serotonin reuptake inhibitors, indirectly linking
it to brain (dys)function (Woo et al., 2015).
4.2. Expression of CSAD and GADL1
The most striking difference between the enzymes was found in
their patterns of tissue expression of both mRNA and protein,
where GADL1 wasmainly found inmuscle and brain, in particularly
olfactory bulb, and CSAD was found in liver, kidney and brain tis-
sues, conﬁrming previous reports (Guion-Rain and Chatagner,
1972; Liu et al., 2012; Park et al., 2014, 2002; Reymond et al.,
1996a; Reymond et al., 2000; Tang et al., 1996; Tappaz et al.,
1994, 1998; Weinstein and Grifﬁth, 1987).
The recent observations that human (Liu et al., 2012) and mouse
GADL1 decarboxylate CSA at comparable rates to CSAD (Table 1),
raised the possibility that the enzyme “CSADII” described by Tang
and coworkers (Tang et al., 1996) is identical to GADL1. This would
explain the reported discrepancies between CSAD enzyme activity
and mRNA levels in different tissues (Tappaz et al., 1999). However,
the low expression levels of GADL1 in adult neurons (Table 3, Fig. 5)
indicate that this enzyme probably cannot account for much of the
CSAD activity previously reported (Tang et al., 1996; Tappaz et al.,
1999). The relative expression levels and catalytic activities of
CSAD and GADL1 are in accordance with the recent study of Park
et al., who found that CSAD knockout mice had a 83% reduction of
plasma taurine levels and a similar reduction in liver and brain
taurine levels in offspring of CSAD/ mice (Park et al., 2014).
Based on our estimates of catalytic activity and expression levels,
GADL1 probably accounts for a small fraction of the remainingTable 3
Gene Expression assay with different mouse and human tissues. Total RNA from
different tissues was analyzed using RT-PCR and normalized against GAPDH. Results
are average ± stdev for three preparations.
Species Tissue CSAD (DCtGAPDH) GADL1 (DCtGAPDH)
Human Brain 8.07 ± 0.78 14.73 ± 0.47
Liver 5.96 ± 0.61 n.d.
Astrocytes 9.02 ± 0.08 15.56 ± 0.36
Neurons 8.33 ± 0.44 11.9 ± 0.54
Mouse Brain 8.06 ± 0.62 13.83 ± 1.45
Liver 6.04 ± 0.55 n.d
Kidney 5.17 ± 0.02 14.86 ± 0.42
Muscle 12.93 ± 0.24 9.85 ± 0.15CSAD activity in CSAD knockout mice, while cysteamine dioxyge-
nase (EC 1.133.11.19) also may contribute to taurine synthesis.
Weinstein and Grifﬁth reported that there was almost no
detectable CSAD mRNA in the brain, whereas they could still
measure enzyme activity (Weinstein and Grifﬁth, 1987). It was
explained by fast turnover of the mRNA, but it could also be due to
the existence of several CSAD enzymes with different mRNA se-
quences (Suppl. Table 2). Western blotting revealed multiple mo-
lecular species. This could be due to alternatively spliced variants,
as there is evidence for alternative splicing for CSAD and GADL1.
The identity and roles of such putative splice variants should be
further investigated.
Taurine has mainly been detected in neurons in the cerebellum
and hippocampus (Ottersen et al., 1988; Zhang and Ottersen, 1992),
and more in fetal tissues than in adults (Terauchi et al., 1998).
However, it is unclear whether biosynthesis of taurine occurs
exclusively in neurons or glial cells, or both cell types. The use of
different antisera may have contributed to the diverging results
reported from different research groups. Chan-Palay and co-
workers found an exclusive localization of CSAD in rat neurons
(Chan-Palay et al., 1982), results that were later conﬁrmed by others
(Kuriyama et al., 1985; Magnusson et al., 1988; Ohkuma et al., 1986;
Taber et al., 1986; Wu et al., 1987). However, other research groups
were not able to detect CSAD in neurons, only in astrocytes
(Reymond et al., 1996b; Tappaz et al., 1992). There are several
theories for these results. It was recently proposed that taurine is
independently produced from cysteine by either astrocytes or
neurons (Vitvitsky et al., 2011), while previous reports indicated
that taurine is produced by a cooperative exchange of taurine
precursors between astrocytes and neurons as each cell type con-
tains incomplete but complementary components of this pathway
(Dominy et al., 2004).
As commercially available antibodies against CSAD do not fully
discriminate between CSAD and GADL1, the ﬁnding of CSAD in both
neurons and astrocytes could potentially be due to cross-reactivity.
However, the RT-PCR data reported here using gene speciﬁc probes
establish that CSAD is present in both neurons and astrocytes,
consistent with the view that taurine biosynthesis takes place
independently in both neurons and astrocytes, and that this activity
cannot be attributed to GADL1, as very low levels of GADL1 were
detected in neurons, and not in astrocytes (Table 3, Fig. 5B). How-
ever, although our data suggest an expression of GADL1 only in the
neurons, The Human Protein Atlas suggest protein expression in
both neurons and glia cells. Non-speciﬁc antibodies, as previously
discussed, could explain these discrepancies.
4.3. Developmental patterns
Our mRNA and protein measurements were compared with
data deposited in the Allen Brain Atlas (http://www.brain-map.org/
) and The Human Protein Atlas http://www.proteinatlas.org/. They
conﬁrm that the PLP-dependent decarboxylases GADL1, CSAD,
GAD65 and GAD67 all have different expression patterns in
humans, as well as in mice, which is consistent with distinct
physiological roles of these proteins. In particular, CSAD and GADL1
have strikingly different patterns of expression in the human brain,
where mRNA levels of GADL1 are lower than CSAD in most brain
regions, except olfactory cortex and ventral striatum (Fig. 7A). In
the latter region, GADL1 mRNA levels appear to be almost 10 fold
higher than for CSAD, indicating a speciﬁc physiological role of
GADL1 in these structures. Our data also suggest that levels of RNA
and protein are lower for GADL1 than for CSAD in most human and
mouse tissues (Figs. 5 and 6), except for muscle and olfactory bulb.
This is consistent with data in the databases Braineac (www.
braineac.org/), Allen Brain Atlas and The Human Protein Atlas.
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as taurine is known to be abundant in this brain structure,
exceeding glutamate and GABA in concentration, and has been
shown to be important in early stages of olfactory maturation
(Steullet et al., 2000).
The highest level of human CSAD mRNA is found during pre-
natal development, with a maximum around 17 weeks post
conception (pcw), although it is also detected inmany brain regions
in adults (Ohkuma et al., 1986). In contrast, GADL1 appears to be
exclusively expressed in brain cortical areas during embryonic
development, with highest levels during 12e14 pcw. Except for
these weeks, CSAD had a much higher level of expression than
GADL1 (Brainspan and Human Brain Atlas). CSAD appears to have
the highest level in the intermediate zone, important for neural
migration, whereas GADL1 has the highest level in the subplate
zone, important in establishing correct wiring and functional
maturation of the cerebral cortex. The subplate neurons disappear
during postnatal development, and this could explain the low
levels of GADL1 in adult brain. When analyzing lysates from total
mouse brain, we obtained similar results (Fig. 7A), although three
lanes of protein bands were observed. These protein bands could
indicate different splice variants. This has not previously been
investigated for GADL1, although it has been reported that alter-
native splicing is frequent during early embryonic development in
mice (Revil et al., 2010). Distinct developmental patterns of
expression have also been described for other PLP-dependent
decarboxylases, such as GAD67 (as shown in Fig. 7A) and AADC
(Blechingberg et al., 2010; Liu et al., 2010). Temporal and organ
speciﬁc splicing events, resulting in many different mRNA and
protein species from these genes, indicates a ﬁne tuned physio-
logical regulation of expression, but has also complicated previous
studies of these enzymes (Blechingberg et al., 2010; Liu et al., 2010).
4.4. Animal models
The physiological roles of CSAD and particularly GADL1 are not
well established. It was recently reported that CSAD is expressed
during early embryonic development of the Zebraﬁsh and that
knockdown of Csad signiﬁcantly reduced embryonic taurine levels,
leading to increased early mortality and cardiac abnormalities
(Chang et al., 2013). This is in line with previous studies on taurine
transporter (TauT) knockout mice, which showed abnormalities of
kidney, liver, brain, retina and olfactory function (Warskulat et al.,
2007). In contrast, the CSAD knockout mice had a less severe
phenotype (Park et al., 2014).
Unlike CSAD, GADL1 is absent from the Zebraﬁsh genome.
Considering the predominantly embryonic pattern of GADL1
expression observed in mice and humans, it is tempting to specu-
late that GADL1 may have a speciﬁc role during embryonic devel-
opment and that this evolutionary more recent enzyme has
replaced some CSAD function in early brain development.
Selective knockdown and knockout studies of GADL1 in com-
bination with CSAD may be needed to resolve the metabolic role of
these enzymes. However, since both CSAD and GADL1 appear to be
transcribed to multiple tissue-speciﬁc transcripts with different in-
frame start codons, comprehensive knockdown experiments of
these enzymes may be technically challenging (Chang et al., 2013).
4.5. PLP-dependent decarboxylases in human disease
Several PLP-dependent decarboxylases act as autoantigens in
different autoimmune disorders, e.g. GAD65 in type 1 diabetes
(Baekkeskov et al., 1990), GAD65 and GAD67 in the neurological
condition Stiff Person Syndrome (Bjork et al., 1994), and AADC
(Rorsman et al., 1995), histidine decarboxylase and CSAD(Skoldberg et al., 2004) in APS-1. Interestingly, autoantibodies
typically recognize evolutionary conserved epitopes on these en-
zymes and act as strong inhibitors of the enzymatic activity, pre-
sumably by binding to epitopes close to the substrate binding or
active sites of the enzymes targeted. We have previously observed
that serum from a subgroup of APS-1 patients (3 out of 83 in-
dividuals) contain antibodies reacting with both CSAD (Skoldberg
et al., 2004) and GADL1 protein produced from a mouse cDNA li-
brary (data not shown). Although APS-1 patients with these auto-
antibodies have multiple autoimmune manifestations, it is unclear
whether they have any pathogenic signiﬁcance.
5. Conclusion
Puriﬁed murine CSAD and GADL1 both decarboxylate CSA, CA,
homocysteic acid and Asp, although with very different afﬁnities.
However, we cannot rule out that these enzymes may have still
other physiological substrates. The novel enzyme inhibitors iden-
tiﬁed by in silico and in vitro screening had relatively low afﬁnities,
but could be used as templates to obtain more selective com-
pounds. The two proteins are located in different tissues. The
possible role GADL1 in olfactory bulb and embryonic brain devel-
opment should be investigated further.
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